NCT07428915Completed
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
A Multi-Reader Multi-Case (MRMC) Study for Assessing the Impact of Legit.Health Plus on the Clinical Assessment of Generalized Pustular Psoriasis and Other Skin Conditions by Healthcare Professionals.
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions. Dermatological issues are common in primary care, but there is often a gap in diagnostic accuracy between general practitioners and specialists, which can lead to treatment delays for serious conditions like Generalized Pustular Psoriasis (GPP) and Hidradenitis Suppurativa (HS). The researchers hypothesized that the AI device would enhance the diagnostic accuracy of healthcare professionals for GPP and other dermatological conditions. To test this, the study followed a prospective observational design involving 15 practitioners, including both general practitioners and dermatologists. During the study, participants were asked to evaluate 100 clinical images. For each case, they first provided a diagnosis based on the image and patient history alone. They were then shown the AI's analysis-which included the top five suggested diagnoses and confidence levels-and asked if they would like to adjust their initial assessment. The primary question the study sought to answer was whether the information provided by the AI device could significantly increase the number of correct diagnoses made by these professionals, particularly for rare diseases that are often difficult to identify in a standard clinical setting
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 15 (actual)
- First submitted
- 18 Feb 2026
- Start date
- 1 Jun 2024
- Primary completion date
- 15 Sept 2024
- Lead sponsor
- AI Labs Group S.L
- Diseases
- Atopic dermatitis (eczema), Psoriasis
- NCT number
- NCT07428915
What you commit to
- Study type: Observational
- Participants enrolled: 15
- From 1 Jun 2024 to the primary completion date, 15 Sept 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Images of patients with pathologies different from GPP or HS that can be easily identified.
Who the study is looking for
- Board-certified general practitioners and dermatologists, regardless of their professional experience.
- Good quality images of patients with GPP.
- Good quality images of patients with HS.
- Good quality images of patients with pathologies that can be confused with GPP or HS, leading to a wrong diagnosis.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AI Labs Group S.L. Coordinator of this site? Confirm its status | Bilbao | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.